---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-24-001681"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:48:53.504167+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Entera Bio Q1 net loss $2.0M; cash $9.2M; FDA catalyst path for EB613

## Summary
- Q1 net loss $2.0M ($0.05 per share) vs $2.2M ($0.08) in Q1 2023.
- Cash $9.2M at March 31, 2024; runway into Q3 2025.
- R&D expenses $0.7M (down from $0.9M); G&A flat at $1.3M.
- FDA to rule on BMD as surrogate for fractures within 10 months – key catalyst for EB613 Phase 3.
- Oral GLP-2 tablets showed 10-fold higher plasma exposure vs teduglutide; OXM PK data expected mid-2024.

## SEC filing metadata
- accession: 0001178913-24-001681
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891324001681/0001178913-24-001681-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891324001681/zk2431441.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-24-001681
- JSON: https://secwatch.observer/filing/0001178913-24-001681.json
- Plain text: https://secwatch.observer/filing/0001178913-24-001681.txt

## Key facts
- Earnings Releases
  Entera Bio Ltd. reported the quarter ended March 31, 2024 results: net income $2.0 million, EPS $0.05 per ordinary share (basic and diluted).
  - Period: the quarter ended March 31, 2024
  - Net income: $2.0 million
  - EPS: $0.05 per ordinary share (basic and diluted)
  - Result: reported results
  source text: Net loss was $2.0 million, or $0.05 per ordinary share (basic and diluted), for the period ended March 31, 2024, as compared to $2.2 million, or $0.08 per ordinary share (basic and diluted), for the period ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891324001681/0001178913-24-001681-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.